LOGIN TO YOUR ACCOUNT

Username
Password
Remember Me
Or use your Academic/Social account:

CREATE AN ACCOUNT

Or use your Academic/Social account:

Congratulations!

You have just completed your registration at OpenAire.

Before you can login to the site, you will need to activate your account. An e-mail will be sent to you with the proper instructions.

Important!

Please note that this site is currently undergoing Beta testing.
Any new content you create is not guaranteed to be present to the final version of the site upon release.

Thank you for your patience,
OpenAire Dev Team.

Close This Message

CREATE AN ACCOUNT

Name:
Username:
Password:
Verify Password:
E-mail:
Verify E-mail:
*All Fields Are Required.
Please Verify You Are Human:
fbtwitterlinkedinvimeoflicker grey 14rssslideshare1
Timsah, Zahra; Ahmed, Zamal; Ivan, Cristina; Berrout, Jonathan; Gagea, Mihai; Zhou, Yong; Pena, Guillermo N. Armaiz; Hu, Xin; Vallien, Courtney; Kingsley, Charles V.; Lu, Yiling; Hancock, John F.; Liu, Jinsong; Gladden, Andrew B.; Mills, Gordon B.; Lopez-Berestein, Gabriel; Hung, Mien-Chie; Sood, Anil K.; Bogdanov, Mikhail; Ladbury, John E. (2015)
Publisher: Nature Publishing Group
Languages: English
Types: Article
Subjects: Article
In the absence of extracellular stimulation the adaptor protein Grb2 and the phospholipase Plcγ1 compete for the same binding site on FGFR2. Reducing cellular Grb2 results in up-regulation of Plcγ1 and depletion of the phospholipid PI(4,5)P2. The functional consequence of this event on signaling pathways are unknown. We show that the decrease in PI(4,5)P2 level under non-stimulated conditions inhibits PTEN activity leading to the aberrant activation of the oncoprotein Akt. This results in excessive cell proliferation and tumor progression in a xenograft mouse model. As well as defining a novel mechanism of Akt phosphorylation with important therapeutic consequences, we also demonstrate that differential expression levels of FGFR2, Plcγ1 and Grb2 correlate with patient survival. Oncogenesis through fluctuation in the expression levels of these proteins negates extracellular stimulation or mutation and defines them as novel prognostic markers in ovarian cancer.

Share - Bookmark

Funded by projects

Cite this article